CytRx Corporation focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8,. and Aldoxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor.
Market Cap | 21.34 Million | Shares Outstanding | 38.8 Million | Avg 30-day Volume | 102.633 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.04 |
Price to Revenue | 0.0 | Debt to Equity | 0.0805 | EBITDA | -11.678 Million |
Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | 15.255 Million |
Current Ratio | 1.366 | EPS Growth | 0 | Quick Ratio | 1.335 |
1 Yr BETA | 0.5354 | 52-week High/Low | / | Profit Margin | 0.0 |
Operating Cash Flow Growth | -136.5921 | Altman Z-Score | -208.9207 | Free Cash Flow to Firm | -8.773 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2022-07-27 | 1 | |
SNOWDY STEPHEN CHIEF EXECUTIVE OFFICER |
|
0 | 2022-01-10 | 0 |
|
50,000 | 2021-12-15 | 0 | |
|
590,247 | 2020-08-14 | 0 | |
KRIEGSMAN STEVEN A CHIEF EXECUTIVE OFFICER |
|
3,668,038 | 2020-08-07 | 0 |
|
600,785 | 2020-08-07 | 0 | |
|
335,373 | 2020-08-07 | 0 | |
CALOZ JOHN Y CHIEF FINANCIAL OFFICER |
|
0 | 2019-12-13 | 0 |
CURTIS ERIC PRES., CHIEF OPERATING OFFICER |
|
0 | 2018-05-03 | 0 |
KRATZ FELIX VICE PRESIDENT DRUG DISCOVERY |
|
0 | 2017-12-15 | 0 |
CHAWLA SHANTA M.D. SENIOR VP-DRUG DEVELOPMENT |
|
2,100 | 2017-06-13 | 0 |
|
0 | 2016-12-15 | 0 | |
LEVITT DANIEL J EVP AND CHIEF MEDICAL OFFICER |
|
0 | 2016-12-15 | 0 |
WIELAND DOUGLAS SCOTT SR VP - DRUG DEVELOPMENT |
|
0 | 2016-12-15 | 0 |
|
0 | 2016-12-15 | 0 | |
WARE OLIVIA C CHIEF COMMERCIAL OFFICER |
|
0 | 2016-01-11 | 0 |
LEVIN BEN SVP-LEGAL AFFAIRS/GC/SECY |
|
0 | 2015-12-15 | 0 |
|
0 | 2015-12-15 | 0 | |
|
0 | 2015-12-15 | 0 | |
|
0 | 2014-12-15 | 0 | |
|
0 | 2013-12-10 | 0 | |
|
0 | 2013-12-10 | 0 | |
|
4,577,605 | 2013-12-10 | 0 | |
GEYER DAVID SCOTT SR. V.P. OF MANUFACTURING |
|
0 | 2011-12-12 | 0 |
BARBER JACK R CHIEF SCIENTIFIC OFFICER |
|
0 | 2009-07-01 | 0 |
SHAH JAISIM SR. VP - BUSINESS DEVELOPMENT |
|
0 | 2009-05-04 | 0 |
FOGELMAN MITCHELL K CHIEF FINANCIAL OFFICER |
|
0 | 2008-11-21 | 0 |
NG SHI CHUNG SR VP RESEARCH & DEVELOPMENT |
|
0 | 2008-11-21 | 0 |
TEPPER MARK VICE PRESIDENT |
|
250,000 | 2007-05-02 | 0 |
NATALIZIO MATT CHIEF FINANCIAL OFFICER |
|
50,000 | 2006-06-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
LADRX CORP LADX | 2023-01-26 22:15:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 21:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 21:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 20:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 20:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 19:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 19:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 18:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 18:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 17:45:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 17:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 16:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 16:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 15:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 15:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 14:45:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 14:15:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 13:45:03 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 13:15:04 UTC | -3.8925 | 8.2125 | 700000 |
LADRX CORP LADX | 2023-01-26 12:45:04 UTC | -3.8925 | 8.2125 | 700000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|